1.04

0.48% -0.01

Clearside Biomedical Inc (CLSD)

Overview News Price History Option Chain Financials Discussions Forecast

Clearside Biomedical Inc stock is traded at $1.04, with a volume of 29,743. It is down -0.48% in the last 24 hours and down -20.83% over the past month. Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Previous Close:

$1.05

Open:

$1.06

24h Volume:

29,743

Relative Volume:

0.04

Market Cap:

$79.17M

Revenue:

$8.23M

Net Income/Loss:

$-32.49M

P/E Ratio:

-1.7627

EPS:

-0.59

Net Cash Flow:

$-19.91M

1W Performance:

-0.48%

1M Performance:

-20.83%

6M Performance:

-29.87%

1Y Performance:

+10.00%

1-Day Range:

$1.04

$1.08

1-Week Range:

$0.9757

$1.08

52-Week Range:

$0.92

$2.12

Clearside Biomedical Inc Stock (CLSD) Company Profile

Name

Clearside Biomedical Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

678-270-3631

Address

900 NORTH POINT PARKWAY, ALPHARETTA, GA

Employee

Twitter

@clearsidebio

Next Earnings Date

2024-11-12

Latest SEC Filings

CLSD's Discussions on Twitter

Compare CLSD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLSD	1.04	79.17M	8.23M	-32.49M	-19.91M	-0.59
VRTX	445.00	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	736.17	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	583.62	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	247.09	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.19	24.49B	3.30B	-501.07M	1.03B	11.54

Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-15-21	Resumed	Wedbush	Outperform
Jul-29-21	Initiated	H.C. Wainwright	Buy
May-13-20	Initiated	ROTH Capital	Buy
Aug-09-19	Downgrade	Needham	Buy → Hold
Nov-05-18	Downgrade	Cowen	Outperform → Market Perform
Nov-05-18	Downgrade	JP Morgan	Overweight → Underweight
Nov-05-18	Downgrade	Stifel	Buy → Hold
Mar-06-18	Reiterated	Needham	Buy
May-25-17	Initiated	JMP Securities	Mkt Outperform
Feb-24-17	Initiated	JP Morgan	Overweight
Nov-10-16	Reiterated	Needham	Buy
Oct-24-16	Reiterated	Stifel	Buy

View All

Clearside Biomedical Inc Stock (CLSD) Latest News

Nov 18, 2024

Clearside Biomedical’s (CLSD) Buy Rating Reaffirmed at HC Wainwright - Defense World

Nov 18, 2024

What is HC Wainwright's Forecast for CLSD FY2024 Earnings? - MarketBeat

Nov 18, 2024

Nov 17, 2024

Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Decline in Short Interest - MarketBeat

Nov 17, 2024

Nov 16, 2024

Clearside Biomedical's (CLSD) Buy Rating Reaffirmed at Chardan Capital - MarketBeat

Nov 16, 2024

Clearside Biomedical (NASDAQ:CLSD) Raised to Hold at StockNews.com - MarketBeat

Nov 16, 2024

All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy - MSN

Nov 16, 2024

Nov 15, 2024

Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 15, 2024

Needham & Company LLC Reaffirms Buy Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World

Nov 15, 2024

Nov 14, 2024

Clearside Biomedical (NASDAQ:CLSD) Given Buy Rating at HC Wainwright - MarketBeat

Nov 14, 2024

Clearside Biomedical Announces Slight Revenue Increase in Third Quarter, Advances Wet AMD Treatment in Clinical Trial - Vision Monday

Nov 14, 2024

Nov 13, 2024

Earnings call: Clearside Biomedical reports progress in AMD treatment - Investing.com

Nov 13, 2024

Earnings call: Clearside Biomedical reports progress in AMD treatment By Investing.com - Investing.com Australia

Nov 13, 2024